Drugs / BCG Tokyo-172 Strain
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03091660 | Feb 2017 → Dec 2025 overdue | bladder carcinoma in situ | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Tokyo-172 Strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03091660 ↗ |
| Modality | Vaccine | “priming with intradermal bacillus Calmette-Guérin (BCG) vaccine prior to standard intravesical BCG improves response to BCG” PMID 30197040 ↗ Sep 2018 |
| Route | Other | “Given intravesically” NCT03091660 ↗ |